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Abstract 
 
Genetic alterations that potentiate PI3K signalling are frequent in prostate cancer, yet how 
different genetic drivers of the PI3K cascade contribute to prostate cancer is unclear. Here, 
we report PIK3CA mutation/amplification correlates with poor prostate cancer patient 
survival. To interrogate the requirement of different PI3K genetic drivers in prostate cancer, 
we employed a genetic approach to mutate Pik3ca in mouse prostate epithelium. We show 
Pik3ca
H1047R
 mutation causes p110-dependent invasive prostate carcinoma in-vivo. 
Furthermore, we report PIK3CA mutation and PTEN loss co-exist in prostate cancer patients, 
and can cooperate in-vivo to accelerate disease progression via AKT-mTORC1/2 
hyperactivation. Contrasting single mutants that slowly acquire castration-resistant prostate 
cancer (CRPC), concomitant Pik3ca mutation and Pten loss caused de-novo CRPC. Thus, 
Pik3ca mutation and Pten deletion are not functionally redundant. Our findings indicate that 
PIK3CA mutation is an attractive prognostic indicator for prostate cancer that may cooperate 
with PTEN loss to facilitate CRPC in patients.  
 
Statement of significance  
We show PIK3CA mutation correlates with poor prostate cancer prognosis and causes 
prostate cancer in mice. Moreover, PIK3CA mutation and PTEN loss co-exist in prostate 
cancer, and can cooperate in-vivo to accelerate tumorigenesis and facilitate CRPC. 
Delineating this synergistic relationship may present new therapeutic/prognostic approaches 
to overcome castration/PI3K-AKT-mTORC1/2 inhibitor resistance. 
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Introduction 
 
Prostate cancer is the second most common male cancer-related death world-wide, 
emphasizing the failure of mainstay therapeutic regimens to treat advanced disease(1). A 
pivotal constraint for prostate cancer research is the lack of diverse in vivo models that 
accurately reflect the clinic. Expanding the range of prostate cancer models that display key 
clinicopathological characteristics is vital to; (i) delineate the complex molecular mechanisms 
underpinning prostate cancer, (ii) identify novel prognostic markers and therapeutic targets, 
and (iii) accurately establish the efficacy of novel therapies that are urgently needed in the 
clinic. 
 
Class 1A phosphatidylinositol 3-kinases (PI3Ks) are heterodimers consisting of a regulatory 
subunit encoded by PIK3R1 (p85/p55α/p50α), PIK3R2 (p85β) or PIK3R3 (p85γ), and a 
catalytic subunit encoded by PIK3CA (p110 PIK3CB (p110or PIK3CD (p110)(2,3). 
Upon activation of receptor tyrosine kinases (RTKs), G-protein coupled receptors (GPCRs) 
or RAS, PI3K is recruited to the membrane. Here, PI3K catalyses the generation of the 
second messenger phosphatidylinositol(3,4,5)trisphosphate (PIP3), which recruits the serine 
threonine kinases AKT (Protein kinase B, PKB) and Phosphoinositide-dependent kinase-1 
(PDK1) to the membrane, as well as a plethora of  other PIP3 binding proteins (4). The first 
identified, and most well studied, PIP3 effector is AKT(4). PDK1 phosphorylates AKT at 
Thr308, leading to phosphorylation of downstream targets including Tuberous Sclerosis 
Complex 2 (TSC2) that activates mTOR complex-1 (mTORC1) to promote proliferation, 
survival and migration(2,3). Phosphorylation of AKT at both Ser473 and Thr308 is required 
for the full activation of AKT, and has been linked to co-activation of the mTORC1 and 
mTOR complex-2 (mTORC2) pathways(5). Key substrates of mTORC2 include AKT at 
Ser473(5), and serum/glucocorticoid regulated kinase-1 (SGK1), which phosphorylates and 
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inactivates the metastasis suppressor N-Myc down-regulated gene-1 
(NDRG1/DRG1/CAP43)(6). AKT dephosphorylation by PH domain leucine-rich repeat 
protein phosphatase (PHLPP) at Ser473 and Protein phosphatase 2 (PP2A) at Thr308 
deactivate AKT(5). The fine tuning of AKT phosphorylation levels mediates AKT pathway 
activity and subsequent cellular events. In addition, the tumor suppressor Phosphatase and 
tensin homolog (PTEN) serves to negatively regulate the PI3K cascade by catalysing the 
dephosphorylation of PIP3
 
to phosphatidylinositol 4,5-bisphosphate (PIP2). PTEN also 
mediates lipid phosphatase-independent tumor suppressor activities via its protein 
phosphatase domain(2).    
 
PI3K pathway hyperactivation is invariably associated with prostate cancer progression in the 
clinic, thus presenting an attractive therapeutic target. Indeed, loss of PTEN, a negative 
regulator of the PI3K pathway, is estimated to occur in 40-50% of prostate cancer 
patients(7,8). However, PI3K pathway hyperactivation can occur via a range of mechanisms 
(e.g. PIK3CA oncogenic mutation) that can independently influence downstream signaling 
events. We sought to determine if genetic drivers of the PI3K pathway that are present in 
prostate cancer, but have not been investigated previously, can also contribute to prostate 
cancer initiation/progression. To this end we generated a new, clinically relevant genetically 
modified mouse model harbouring a heterozygous activating mutation in Pik3ca specifically 
within prostate epithelial cells, and compared prostate histopathology with the well-
characterised Pten-deleted mouse model of prostate cancer(9). Overall, our findings 
emphasize the prognostic value of PI3K genetic drivers to better inform personalised therapy 
design. 
 
Results 
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PIK3CA mutation/amplification correlates with advanced prostate cancer progression. 
PIK3CA oncogenic mutation and amplification, which may increase p110 PI3K catalytic 
activity, are frequently detected in human cancers (10-13). To better understand the 
frequency of PIK3CA alterations in prostate cancer, we analysed nine prostate cancer 
genomic datasets for PIK3CA mutations and gene amplification(14). Our analysis shows that 
PIK3CA mutations occur in up to 4% of prostate cancer patients, while PIK3CA copy number 
gain/amplification occurs in as many as 62% of cases (Fig.1A, Supplementary Table 1). 
PIK3CA mutations were predominantly nucleotide missense substitutions (87.5%, 
Supplementary Fig.1A) within the helical (44.1%) and kinase (20.6%) domains, and 
previously reported hotspot mutations in exon 9 (E542K, E545K) and 20 (H1047R)(10-
12,15) were most frequent (Fig.1B). Notably, the majority of PIK3CA mutations observed 
(83%, 19/23) have been previously detected in prostate or non-prostate 
malignancies(12,13,15,16), and are reported to increase p110 activity(12,15-18) (Fig.1B).  
 
To determine if PIK3CA mutation/amplification correlates with prostate cancer progression, 
we analysed the TCGA provisional prostate cancer dataset (Supplementary Table 2). Our 
analysis revealed that PIK3CA mutation and copy number gain/amplification frequency 
significantly correlates with poor prostate cancer survival, regional lymph node metastasis, 
and a higher pT category and Gleason grade (Fig.1C, Supplementary Table 3), resembling 
PTEN loss (Supplementary Fig.1B, Supplementary Table 4).  
 
Co-expression analysis within the nine prostate cancer datasets analysed revealed that 39.4% 
(13/33 patients) of PIK3CA mutation carriers also harboured PTEN mutation or copy number 
loss, indicating that PIK3CA mutant prostate cancer patients have a high frequency of co-
existent PTEN deleterious genetic alterations, consistent with ovarian, breast, endometrial, 
Research. 
on April 27, 2018. © 2018 American Association for Cancercancerdiscovery.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on March 26, 2018; DOI: 10.1158/2159-8290.CD-17-0867 
Pik3ca mutation drives prostate cancer 
8 
 
and colorectal cancer studies(11,19,20). Interestingly, 47.5% (96/202) of prostate cancer 
patients with PIK3CA amplification/gain also carried a PTEN mutation or copy number loss. 
Moreover, statistical analysis of the larger TCGA provisional dataset revealed a significant 
tendency towards PIK3CA mutation/amplification/gain and PTEN mutation/loss co-
occurrence in prostate cancer patients (P<0.001, Fisher’s exact test, Log odds ratio = 0.916). 
Together, these findings suggest that PIK3CA mutation/amplification/gain play an oncogenic 
role during prostate cancer and indicate that p110 gain-of-function and PTEN loss may 
cooperate to promote prostate cancer growth.  
 
Pik3ca
H1047R
 mutation in mouse prostate epithelium causes locally invasive prostate 
carcinoma. To delineate the oncogenic role of a clinically relevant PIK3CA mutation within 
the prostate, we inter-crossed mice that harbor a conditional latent H1047R mutation in 
Pik3ca to the PBiCre transgenic line. Using an exon-switch Cre-LoxP approach, expression 
of Pik3ca
H1047R
 was driven specifically within the prostate following PBiCre-mediated 
excision of the floxed wild-type (Wt) Pik3ca exon 20 and subsequent expression of a latent 
downstream mutant exon 20(11,21). Recombination was confirmed by sequencing and allele-
specific PCR analysis of cDNA isolated from the prostate glands of PBiCre
+/-
;Pik3ca
+/+
 and 
PBiCre
+/-
;Pik3ca
+/Lat-H1047R
 mice, hereafter referred to as Wt and Pik3ca
+/HR
 respectively 
(Supplementary Fig.2A-B). Histological analysis of Wt and Pik3ca
+/HR
 prostate lobes 
revealed no gross phenotype in Wt mice, whereas Pik3ca
+/HR
 cohorts displayed a progressive 
malignant phenotype. Pik3ca
+/HR
 mice developed multifocal simple and/or cribriform 
hyperplasia in all prostate lobes by 100 d and homogeneous, locally invasive prostate 
carcinoma by 300–400 d (dorsolateral lobe: Fig.2A-B, and ventral/anterior lobes: 
Supplementary Fig.2C-E, Supplementary Table 5). Invasion was confirmed by the absence of 
smooth muscle actin (SMA) staining by immunohistochemistry (IHC) (Supplementary 
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Fig.2F).  Pik3ca
+/HR
 prostate carcinomas were predominantly dysplastic/mucinous and 
reactive stroma and immune infiltrate were evident (Fig.2A; 300-400 d, Supplementary 
Fig.2C). Taken together, these data demonstrate that heterozygous Pik3ca
H1047R
 oncogenic 
mutation is sufficient to cause invasive prostate cancer in mice, and to our knowledge is the 
first example of a mono-allelic mutation driving invasive prostate cancer growth in vivo. 
 
To determine if the genetic driver of the PI3K cascade influences prostate tumorigenesis 
and/or malignant progression, we compared our novel Pik3ca
+/HR
 prostate cancer model with 
the well-characterised Pten-deleted mouse model of prostate cancer(9). To this end, we 
generated age-matched cohorts of PBiCre
+/-
;Pten
fl/fl
 mice (denoted Pten
fl/fl
) deficient for both 
copies of Pten within prostate epithelial cells and compared the phenotype on the same 
genetic background. In contrast to Pik3ca
+/HR
 mice, we observed early onset of hyperplastic 
lesions at 56 d and rapid tumor progression from prostate intraepithelial neoplasia (PIN) to 
locally invasive carcinoma in Pten
fl/fl
 mice by 200 d (Fig.2A-B, Supplementary Fig.2C-E, 
Supplementary Table 5). Furthermore, Pten
fl/fl
 prostate tumor burden was significantly greater 
and more heterogenous than the Pik3ca
+/HR
 model (Fig.2A/C), as carcinosarcomas were also 
present by 300 d in 29% of the cohort (2/7). However, metastasis to the liver, lung, lymph 
nodes or bone was not detected in either model. Pten
fl/fl
 mice were also prone to seminal 
vesicle neoplasia, urethra neoplasia and adrenal pheochromocytoma that were rare, or absent, 
in Pik3ca
+/HR
 mice (Supplementary Table 5). These findings indicate that relative to the 
Pik3ca
+/HR
 model, early disease onset, and potentially accelerated progression, contribute to 
the earlier emergence of invasive carcinoma in Pten
fl/fl
 mice.  
 
To investigate if Pten bi-allelic loss accelerates prostate tumor growth compared to 
Pik3ca
+/HR
-driven prostate cancer,
 
we performed and quantitated IHC to detect the S-phase 
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proliferation marker PCNA. Pik3ca
+/HR
 prostate disease (100–400 d) showed a significant 
increase in the number of PCNA-positive proliferating cells compared to Wt controls, 
however a clear proliferation advantage was evident in Pten
fl/fl
 mice between 56–200 d 
(Fig.3A-B). Furthermore, significantly more PCNA-positive cells were detected in Pten
fl/fl
 
prostate hyperplasia compared to Pik3ca
+/HR
 hyperplastic lesions (Supplementary Fig.2G), 
indicating this is an early phenomenon during disease progression. These data show that 
increased proliferation in Pten
fl/fl
 mice facilitates accelerated prostate cancer progression 
compared to Pik3ca
+/HR
 mice. Notably, apoptosis evasion is not likely to contribute to 
accelerated disease progression in Pten
fl/fl
 mice, as the number of cleaved-caspase-3 (CC3)-
positive apoptotic cells was largely increased in Pten
fl/fl
 prostate epithelium compared to age-
matched Pik3ca
+/HR
 mutants (Supplementary Fig.3A-B). IHC analysis to detect prostate basal 
and luminal cell markers cytokeratin-5, (CK5) and cytokeratin-8 (CK8) respectively, revealed 
that, unlike Pten
fl/fl
 prostate tumors, Pik3ca
+/HR
-driven tumors are predominantly comprised 
of luminal epithelial cells and rarely display expansion/mislocalization of the CK5-positive 
basal cell population (Supplementary Fig.3C). Taken together these data show that while a 
single Pik3ca H1047R activating mutation predisposes to murine prostate cancer, like bi-
allelic loss of Pten, these two genetic drivers of the PI3K cascade do not completely 
phenocopy. Overall, these findings suggest that Pik3ca oncogenic mutation and Pten loss 
may drive prostate tumor phenotypes via distinct molecular mechanisms, which could present 
novel therapeutic targets. 
 
Pik3ca mutation and Pten loss stimulate mTORC1 signaling to promote prostate 
tumorigenesis and facilitate malignant progression in mice. Given that both Pten deletion 
and Pik3ca oncogenic mutations can activate PI3K signaling, the phenotypic differences 
observed between the genetic drivers could reflect differential activation of the PI3K cascade. 
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To determine if PTEN tumor suppressive function is maintained in the Pik3ca
+/HR
 model, we 
performed IHC to detect PTEN. We observed uniform membranous PTEN staining in Wt 
prostate epithelium and Pik3ca
+/HR
 tumors, whereas PTEN-positive cells were absent in 
Pten
fl/fl
 prostate tumors, consistent with bi-allelic Pten ablation (Fig.3C). To determine if 
PTEN impairs effector cascades downstream of PI3K in the Pik3ca
+/HR
 model to delay 
prostate tumorigenesis and progression, we evaluated AKT activation and the status of the 
PI3K downstream mechanistic target of rapamycin (mTOR) effector cascades. mTOR is a 
serine/threonine kinase that forms part of two distinct complexes; mTORC1 and mTORC2. 
We show that the number of prostate epithelial cells displaying activation of AKT via Thr308 
phosphorylation at the cell membrane, is significantly increased in Pik3ca
+/HR
 and Pten
fl/fl
 
prostate carcinoma compared to Wt controls (Fig.3C-D), indicating that both PI3K genetic 
drivers stimulate mTORC1 signaling to promote tumor growth. In support, the proportion of 
cells displaying phosphorylation of well-known downstream mTORC1 targets, namely the 
ribosomal protein S6 (RPS6) at Ser235/236 that regulates cell size and proliferation and 4e-
binding protein 1 (4E-BP1) at Thr37/46 that mediates translational machinery, were also 
significantly elevated in both models (Fig.3C, E-F). Our analysis of the number of p-AKT 
(Thr308), p-RPS6 and p-4E-BP1 positive cells in Pten
fl/fl
 and Pik3ca
+/HR
 hyperplastic lesions 
also revealed that mTORC1 signaling upregulation occurs pre-malignancy (Supplementary 
Fig.3D-G). Of note, the number of p-RPS6 and p-4E-BP1 positive cells were comparable in 
Pik3ca-mutated and Pten-deleted hyperplastic lesions and advanced tumors, despite 
significantly more p-AKT (Thr308) positive cells being detected in the Pten
fl/fl
 model, 
suggesting that p-AKT Thr308 independent phosphorylation of RPS6 and p4E-BP1 may 
occur, or that the partial increase in p-AKT Thr308 in Pik3ca
+/HR
 tumors is sufficient to 
sustain p-RPS6 and p-4E-BP1 signaling. Taken together, these data indicate that both Pik3ca 
H1047R oncogenic mutation and Pten bi-allelic loss stimulate mTORC1 signaling to 
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facilitate prostate tumor formation and progression, and that PTEN-mediated tumor 
suppressive functions do not impair mTORC1 downstream signaling in the context of Pik3ca
 
mutation.  
 
Relative to Pik3ca
 
mutation, Pten deletion augments mTORC2 signaling to further 
promote prostate tumor formation and progression in mice. Since activation of the 
mTORC1 downstream targets was comparable between Pik3ca
+/HR
 and Pten
fl/fl
 prostate 
cancer models, we reasoned that the early onset and accelerated progression observed in the 
Pten
fl/fl
 model may be attributable to mTORC2 signaling. To investigate this, we performed 
and quantitated IHC in Pik3ca
+/HR
 and Pten
fl/fl
 prostate carcinomas to detect the 
phosphorylation of two mTORC2 targets; AKT at Ser473 and NDRG1 at Thr346. We show 
that the number of p-AKT Ser473 and p-NDRG1 Thr346 positive cells was significantly 
increased in Pten
fl/fl
 prostate tumors compared to the Pik3ca
+/HR
 model and Wt controls 
(Fig.3C,G-H). Similar results were observed when comparing hyperplastic lesions 
(Supplementary Fig.3D,H-I). Thus, mTORC2 signaling presents a direct mechanism whereby 
Pten homozygous deletion can promote tumor onset/progression relative to Pik3ca
 
H1047R 
oncogenic mutation in this setting.   
 
Pik3ca H1047R mutation causes p110-dependent prostate cancer. Recent reports have 
demonstrated that p110 and p110 isoforms of the PI3K catalytic subunit play distinct 
cellular functions and are regulated independently by differential binding partners(22-25). 
For instance, in vitro assays have established that Ras subfamily members can directly bind 
to the Ras binding domain (RBD) of p110 (and not p110 to activate p110 kinase 
activity, and p110 RBD:RAC1 interactions have been shown to be required for GPCR-
mediated p110 signaling(22-24). Moreover, Pten-deleted prostate cancers are considered to 
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preferentially activate the p110 isoform, and p110 blockade has been shown to activate 
p110 owing to relief of feedback inhibition (e.g. via IGF1R)(25-28). Thus, we sought to 
determine if the phenotypic difference between Pten loss and Pik3ca oncogenic mutation 
reflects differential activation of PI3K catalytic isoforms. To this end, we performed IHC to 
detect p-ERK, a downstream target of the RAS cascade, and activation of RAC1 GTPase in 
Pik3ca
+/HR
 and Pten
fl/fl
 prostate tumors to distinguish activation of RAS-p110 and RAC1-
p110 signaling axes respectively. We find that p-ERK expression is markedly elevated in 
Pik3ca
+/HR
 and Pten
fl/fl 
prostate tumors compared to age-matched Wt controls, indicating 
p110 signaling is activated in both models (Fig.4A). However, only Ptenfl/fl prostate tumors 
displayed Active-RAC-1 GTP staining (Fig.4B), indicating that activation of p110 signaling 
may promote prostate cancer growth induced by Pten-deletion.  
 
To directly test p110 and p110 isoform dependency in Pik3ca mutant and Pten deleted 
prostate cancers, we administered isoform specific inhibitors (A66, a p110-specific inhibitor 
or TGX-221, a p110-specific inhibitor) or a pan-PI3K inhibitor (BKM120) to cohorts of 
Pik3ca
+/HR
 and Pten
fl/fl
 mice with prostate carcinoma for 4 weeks. Pik3ca
+/HR
 tumor burden 
regressed significantly in response to A66 and BKM120 while TGX-221 had no effect, 
indicative of p110-dependency (Fig.4C). In contrast, Ptenfl/fl tumor burden was not reduced 
upon single isoform specific inhibitor treatment but did respond to BKM120 or combined 
A66 and TGX-221 therapy, suggesting Pten-deleted tumors are p110/p110co-dependent 
(Fig.4D). Histopathological analysis of prostate lobes confirmed tumor regression in A66 and 
BKM120 treated Pik3ca
+/HR
 mice, and BKM120 treated Pten
fl/fl
 mice (Fig.4E, Supplementary 
Fig.4A-C). These data suggest that p110mediated signaling events could facilitate Pten-
deleted prostate cancer but not Pik3ca H1047R mutated prostate cancer, and support previous 
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work showing that combined p110and p110 blockade improves therapeutic outcome in 
PTEN-deficient prostate cancers compared to PI3K isoform specific monotherapy(22,26,28). 
Indeed, PI3K pathway inhibitors on their own have been shown to have limited efficacy in 
the clinic due to multiple feedback loops, PI3K-independent pathways and/or additional 
oncogenic mutations, and can cause side effects (e.g. hyperglycemia)(22,26,28,29). Thus, 
treatment approaches that combine PI3K pathway inhibitors with other therapeutic agents are 
currently being explored to improve prostate cancer patient outcome.”  
  
Pten-deletion and Pik3ca
+/HR
 mutation cooperate to accelerate prostate cancer 
progression in mice. Given that we have found that PIK3CA mutation and PTEN loss are not 
mutually exclusive events in prostate cancer patients, we sought to generate a new clinically 
relevant model of prostate cancer, and to test if PI3K genetic drivers can cooperate to 
facilitate prostate cancer growth. Hence, we crossed Pik3ca
+/HR
 mutants with Pten
fl/fl
 animals 
to develop PBiCre
+/-
;Pik3ca
+/HR
;Pten
fl/fl
 compound mutants (termed Pik3ca
+/HR
;Pten
fl/fl
) that 
harbour Pik3ca
+/HR
 mutation and bi-allelic Pten loss in prostate epithelial cells. At 56 and 100 
d we observed aggressive, locally invasive carcinoma with 100% incidence in all 
Pik3ca
+/HR
;Pten
fl/fl
 prostate lobes (Fig.5A-B, Supplementary Fig.5A-B, Supplementary Table 
5). IHC analysis revealed that Pik3ca
+/HR
;Pten
fl/fl
 prostate tumors resemble Pten
fl/fl
 tumors, 
where the CK5+ basal cell population is expanded/mislocalized and the CK8+ luminal cells 
are predominant (Supplementary Fig.5C). Local invasion was confirmed by the absence of 
SMA staining (Supplementary Fig.5C). Tumor burden was also significantly greater in 
compound mutants than age-matched single mutants (Supplementary Fig.5D). Visceral 
metastases were not detected by 100 d of age, and the development of non-prostate 
malignancies reflecting leaky PBiCre-mediated recombination (predominantly benign buccal 
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mucosal/cutaneous papillomas and penile prolapse) prevented further ageing of 
Pik3ca
+/HR
;Pten
fl/fl 
mice.   
 
To investigate the mechanism underpinning cooperation between Pik3ca mutation and Pten 
loss, we determined the number of proliferative and apoptotic cells in Pik3ca
+/HR
, Pten
fl/fl
 and 
Pik3ca
+/HR
;Pten
fl/fl
 locally invasive prostate carcinomas by PCNA and CC3 IHC respectively. 
We show that compound mutant tumors have significantly more PCNA-positive proliferating 
cells than single mutants (Fig.5C-D), while CC3-mediated apoptosis is unaltered 
(Supplementary Fig.5E-F). These findings indicate that Pik3ca
 
oncogenic mutation and Pten 
loss synergize to accelerate prostate cancer progression by increasing proliferation, but not 
survival.  
 
To ascertain if the increased proliferation in Pik3ca
+/HR
;Pten
fl/fl
 mice reflects further 
activation of mTORC1/2 signaling, we performed IHC to detect p-AKT Thr308 that leads to 
mTORC1 activation, as well as the phosphorylation of known mTORC1/2 downstream 
signaling targets. Quantitation of IHC staining revealed that the number of cells expressing 
membranous p-AKT Thr308 is significantly increased in Pik3ca
+/HR
;Pten
fl/fl 
prostate 
carcinomas compared to stage-matched single mutants (Fig.5E and Supplementary Fig.5G). 
In accordance, mTORC1 downstream targets, p-RPS6 and p-4E-BP1 positively correlated 
with p-AKT Thr308 activation (Fig.5F-G, Supplementary Fig.5G), indicating increased 
mTORC1 signaling accelerates prostate cancer growth in Pik3ca
+/HR
;Pten
fl/fl
 mutants. 
Phosphorylation of mTORC2 downstream targets p-AKT Ser473 and p-NDRG1 was also 
significantly increased in compound mutants compared to single mutants (Fig.5H-I, 
Supplementary Fig.5G). Taken together, these findings suggest that further potentiation of 
mTORC1 and mTORC2 signaling, which correlates with super-activation of AKT at 
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Thr308/Ser473, contributes to the cooperative relationship between Pik3ca mutation and Pten 
loss during prostate cancer in this setting.  
 
Previous work has shown that amplification/overexpression of Pik3ca and Pik3cb increases 
oncogenicity(22,30,31), and amplification frequently correlates with poor patient outcome in 
multiple malignancies(22). To establish if Pik3ca/b transcripts are expressed at physiological 
levels in Pik3ca
+/HR
, Pten
fl/fl
 and Pik3ca
+/HR
;Pten
fl/fl
 prostate carcinomas, we performed RNA 
in situ hybridisation, and quantitated RNA molecules relative to Wt controls. We show that 
Pik3ca and Pik3cb mRNA is significantly increased in double mutant prostate tumors 
compared to Pten
fl/fl
 and Pik3ca
+/HR
 single mutant tumors, and age-matched Wt controls 
(Fig.5J-L, Supplementary Fig.5H). However, the functional consequence(s) of Pik3ca and 
Pik3cb mRNA upregulation remain elusive. 
 
Pik3ca
+/HR 
and Pten
fl/fl
 induced prostate cancers acquire CRPC in mice. PTEN loss is 
widely reported to correlate with resistance to androgen deprivation therapy in prostate 
cancer patients and mice(9,32,33). To examine if Pik3ca
+/HR
-driven prostate cancer also 
confers castration resistant disease, we aged cohorts of Pik3ca
+/HR
 mutant mice until invasive 
prostate carcinoma had developed (300 d) and assessed the early and long-term response to 
surgical castration. Although we observed a significant reduction in Pik3ca
+/HR
 total prostate 
weight at 2 and 10 weeks post-castration (Fig.6A), histopathological analysis revealed that 
prostate tumors were still present in Pik3ca
+/HR
 mice, indicating the development of acquired 
CRPC (Fig.6B, Supplementary Fig.6A). These findings are in keeping with partial androgen 
sensitivity and the latent acquisition of CRPC, mirroring homozygous deletion of Pten 
(Fig.6A and B, Supplementary Fig.6A), as previously reported(33,34). IHC to detect AR 
confirmed the reduction of androgens post-castration, as cytoplasmic AR was detected in 
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Pik3ca
+/HR
 and Pten
fl/fl
 prostate epithelial cells following castration, whereas uncastrated 
controls displayed active nuclear AR (Supplementary Fig.6B). 
 
To determine if Pik3ca
 
heterozygous oncogenic mutation sensitises pre-neoplastic prostate 
epithelium to CRPC transition, we examined the short-term and long-term response of 
Pik3ca
+/HR
 mice to castration at 100 d, when only hyperplastic disease is present. Prostate 
epithelial regression was detected 2 weeks post-castration and correlated with a reduction in 
prostate weight, yet small prostate hyperplastic and dysplastic tumors, resembling uncastrated 
Pik3ca
+/HR
 mutants, had developed by 42 weeks post-castration in 100% (6/6) and 67% (4/6) 
of cases respectively (Supplementary Fig.6C-D). These data demonstrate that Pik3ca-mutated 
prostate epithelium possesses an inherent ability to acquire CRPC, similarly to Pten loss(9). 
 
Pik3ca
 
oncogenic mutation and Pten
 
loss synergize, predisposing to de novo CRPC. Next, 
we castrated Pik3ca
+/HR
;Pten
fl/fl
 mice at 100 d of age when invasive carcinoma was present, to 
test if Pik3ca mutation and Pten loss can also cooperate to promote CRPC growth. At 2 
weeks post-castration, castrated compound mutants phenocopied intact controls, and no 
appreciable difference in tumor burden was detected (Fig.6C-D). These findings contrast the 
partial regression observed in the single mutants and indicate that Pik3ca oncogenic mutation 
and Pten homozygous deletion cooperate to promote de novo CRPC in vivo. In support, 
single mutants displayed a significant reduction in the percentage of PCNA-positive 
proliferative cells and elevated CC3-positive apoptotic cells 2 weeks post-castration, which 
were unaltered in compound mutants (Fig.6E-F, Supplementary Fig.7A-B). These data 
indicate that de novo CRPC in Pik3ca
+/HR
;Pten
fl/fl
 mice is attributable to both the sustained 
level of proliferation and castration-induced apoptosis evasion. In accordance with de novo 
CRPC, IHC to detect AR also revealed that a noticeable proportion of Pik3ca
+/HR
;Pten
fl/fl
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prostate epithelial cells displayed AR activation (i.e. nuclear translocation) 2 weeks post-
castration, which were not apparent in single mutants at this early time point (Supplementary 
Fig.6B). Of note, Nkx3.1 and Pbsn, AR transcriptional target genes, are significantly reduced 
in Pik3ca
+/HR
 prostate carcinomas relative to Wt prostate, and levels were further diminished 
in Pten
fl/fl 
and
 
Pik3ca
+/HR
;Pten
fl/fl
 tumors (Supplementary Fig.7C-D). These findings support 
previous work indicating that PI3K activation perturbs AR-mediated signaling(29), and 
indicate that Pbsn and Nkx3.1 transcription is not likely to facilitate de novo CRPC in this 
setting. 
 
The molecular mechanisms underpinning the emergence of CRPC are largely unknown. 
Pten-deleted CRPC acquisition has been previously associated with elevated AKT signaling, 
suggesting that further activation of the AKT cascade contributes to CRPC transition(9). In 
support, we observed a significant increase in the percentage of cells positive for mTORC1 
signaling components p-AKT (Thr308), p-RPS6 (Ser235/236) and p-4E-BP1 (Thr37/46) and 
the mTORC2 target p-AKT (Ser473) in both the Pik3ca
+/HR
 and Pten
fl/fl
 models just 2 weeks 
post-castration (Fig.7A-D). Notably, phosphorylation of NDRG1 was not altered in either 
model post-castration (Fig.7E). Thus, Pten-deleted and Pik3ca-mutated prostate epithelial 
cells appear to hyperactivate AKT upon castration, which elevates mTORC1 signaling 
downstream targets to facilitate CRPC transition. Nevertheless, we do not exclude the 
possibility that additional molecular events may also contribute to CRPC transition in these 
models, including PTEN and/or AKT signal transduction independent of PI3K(2,35).  
 
Our analysis of Pik3ca
+/HR
;Pten
fl/fl
 prostate tumors pre- and post-castration revealed that the 
high proportion of p-AKT (Thr308), p-RPS6 (Ser235/236) and p-AKT (Ser473) positive cells 
is maintained at a super-activated state, and that the percentage of p-4E-BP1 (Thr37/46) and 
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p-NDRG1 (Thr346) cells is increased even further (Fig.7A-E). Despite an increase in p-4E-
BP1 in Pten
fl/fl
 and Pik3ca
+/HR
;Pten
fl/fl
 castrated tumors compared to Pik3ca
+/HR
 castrated 
animals, p-4E-BP1 was not significantly elevated in compound mutants compared to the 
Pten
fl/fl
 model, signifying 4E-BP1 phosphorylation at Thr37/46 and subsequent inactivation 
are not likely to promote de novo CRPC formation.  However, our findings suggest that 
NDRG1 inactivation may contribute to de novo CRPC. In addition to increased 
phosphorylation of NDRG1 post-castration, androgen deprivation in Pik3ca
+/HR
;Pten
fl/fl
  mice 
also positively correlated with p-NDRG1 nuclear localisation (Fig.7F). Nevertheless, the 
precise role of NDRG1 inactivation during de novo CRPC remains to be determined and 
warrants further investigation. Taken together, these results infer that a high threshold of 
AKT-hyperactivation prior to castration, and/or NDRG1-inactivation, may prove to be useful 
biomarkers of intrinsic CRPC in the clinic. 
 
To explore potential mechanisms underpinning the synergistic relationship between Pik3ca 
mutation and Pten-deletion, and during castration-resistant disease formation, we performed a 
reverse-phase protein array (RPPA) on protein lysates isolated from Pik3ca
+/HR
, Pten
fl/fl
 and 
Pik3ca
+/HR
; Pten
fl/fl
 stage-matched uncastrated prostate carcinomas, and 2-weeks post-
castration (Fig.7G, Supplementary Tables 6/7). RPPA data analysis revealed that Pik3ca-
mutated and Pten-deleted prostate tumors display distinct RPPA profiles, supporting the 
contention that Pik3ca oncogenic mutation and Pten loss may mediate distinct signaling 
events to facilitate prostate cancer growth. For instance, compared to Pik3ca
+/HR
 tumors, 
Pten
fl/fl
 tumors displayed enhanced signal intensities for PI3K cascade phosphoproteins (e.g. 
p-AKT Thr308, p-AKT Ser473, p-FOXO3A Ser318/321, p-GSK-3 Ser9 and p-NDRG1 
Thr346), whereas tyrosine kinase-mediated (p-EGFR Tyr1173, p-SHP-2 Tyr542, p-SRC 
family Tyr416) and MAPK (p-ERK1/2 Thr202/Tyr204) phosphoproteins were elevated in 
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Pik3ca
+/HR
 tumors (Fig.7G and Supplementary Table 7). Interestingly, Pik3ca
+/HR
 and Pten
fl/fl
 
prostate carcinomas did not display significant differences in RPPA signal intensities for the 
senescence markers p21 or p27 (Fig. 7G, Supplementary Table 7), suggesting that the 
observed phenotypic differences are not due to changes in senescence. A significant increase 
in p53 signal intensity was observed in Pten
fl/fl 
tumors relative to Pik3ca
+/HR
 tumors. As p21 
and p27 are unaltered, these findings indicate that the observed changes in p53 are not 
regulating senescence, but may instead be mediating other cellular functions, such as 
apoptosis. This correlates with our observations in CC3 and phosphorylated p53 (Ser15) 
(Fig.7G, Supplementary Fig.3B, Supplementary Table 7).  RPPA results for p-AKT Thr308 
and p-AKT Ser473 were confirmed by Western blotting (Supplementary Fig.7E).  
 
RPPA profiles for uncastrated and castrated compound mutants were strikingly similar. 
Indeed, only 4 targets were significantly altered; p-SHP-2 (Tyr542) and p-SRC family 
(Tyr416) signals were increased and YAP and CK2 were decreased (Fig.7G, Supplementary 
Table 7). This result contrasts single mutants that acquired CRPC and is consistent with the 
general lack of effect of castration on the prostate tumors in the double mutant mice (Fig.6C-
F). However, it should be noted that the RPPA was not sensitive enough to detect elevated p-
NDRG1 (Thr346) in Pik3ca
+/HR
;Pten
fl/fl
 mutants post-castration that was observed by IHC 
(Fig.7E-F), presumably owing to tumor heterogeneity and/or stromal content, which may also 
be a contributing factor in the lack of significant difference in other proteins as well. 
Nevertheless, distinct differences between the Pik3ca
+/HR
 and Pten
fl/fl
 models were detected 
post-castration (Fig.7G, Supplementary Table 7). For instance, Pik3ca-mutated tumors 
displayed a significant increase in IGF1R and p-NF-kB p65 (Ser 536) signal intensities 
post-castration, which were not altered in Pten-deleted tumors post-castration. Additionally, 
castrated Pik3ca
+/HR
 tumors displayed elevated JAK/STAT and MAPK signaling relative to 
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castrated Pten
fl/fl
 tumors. Taken together, our findings suggest that Pik3ca oncogenic 
mutation and Pten loss may mediate distinct signaling events to facilitate prostate cancer 
growth and resistance to castration.  
 
Discussion 
We report that PIK3CA mutation/amplification positively correlates with poor prostate cancer 
patient prognosis and overall survival. Our findings are the first to demonstrate that the 
PIK3CA H1047R oncogenic mutation is sufficient to cause invasive prostate cancer in vivo 
and that concomitant loss of PTEN and PIK3CA mutation, which frequently occurs in the 
clinic, can cooperate to accelerate prostate cancer growth in mice.  
 
Our data support the hypothesis that different genetic drivers of the PI3K cascade are not 
functionally redundant, but instead drive prostate tumorigenesis via distinct signaling events. 
We show that relative to p110-dependent Pik3ca+/HR-induced prostate cancers, Ptenfl/fl 
prostate tumors are p110/ co-dependent, and exhibit accelerated tumor formation and 
progression owing to AKT-hyperactivation, elevated mTORC2 and RAC1-p110 signaling. 
The failure to induce robust AKT signaling in Pik3ca
+/HR
 epithelium is probably attributable 
to the maintenance of PTEN tumor suppressive function that reduces PIP3 levels, AKT 
membrane recruitment, and subsequent activation of AKT, as previously reported(35). In 
corroboration, Pten loss has been shown to positively correlate with disease progression in 
mice, as Pten loss of heterozygosity is required for prostate cancer growth in Pten 
heterozygous prostate epithelium(9). We speculate that PTEN function is also likely to be 
conserved in transgenic mice expressing myristoylated/activated AKT or p110 in prostate 
epithelial cells, as only low-grade prostate epithelial neoplasia develops that does not 
progress to carcinoma with ageing(36,37). Taken together, these observations suggest that 
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additional mTORC2/RAC1/p110-independent cooperative events are likely to facilitate 
malignant progression to an invasive state in Pik3ca
+/HR
 mutants that express PTEN. Indeed, 
PIK3CA mutations have been shown to potentiate a PDK1-SGK3, AKT-independent 
signaling axis in various human cancer cell lines that express PTEN(35), and PDK1-SGK1 
AKT-independent signaling has been shown to cause resistance to p110 inhibition by 
directly phosphorylating TSC2 to activate the mTORC1 pathway(38).  
 
Guertin and colleagues have previously shown that RICTOR, a key regulatory component of 
mTORC2, is required for PC3 PTEN-null human prostate cancer cells to form tumor 
xenografts, and that bi-allelic deletion of Rictor prevents prostate cancer formation driven by 
Pten loss in mice by reducing proliferation and AKT phosphorylation at Ser473(39). We 
show that Pten
fl/fl
 mice displayed early prostate tumor formation and accelerated progression 
relative to Pik3ca
+/HR
 mutants, reflecting elevated mTORC2 signalling and subsequent AKT 
phosphorylation at Ser473 in the context of Pten loss. Thus, our findings support the notion 
that mTORC2 signalling plays a critical role during prostate tumorigenesis and progression, 
and strengthen the rationale for mTORC2-targeted therapy in PTEN-deleted prostate cancer. 
 
The absence of p-AKT Ser473 phosphorylation in Pik3ca
+/HR
 mutant prostate cancer may be 
attributable to reduced PIP3 levels and/or distinct AKT regulation in Pten-null and Pik3ca 
mutant prostate cancers, as AKT phosphorylation is dependent on a plethora of AKT protein 
kinases and phosphatases(5). Of note, the mechanism of AKT regulation may also depend 
upon the type of PIK3CA mutation (i.e. helical vs kinase) and tissue context, as several 
human cancer cell lines with PIK3CA kinase mutations have been shown to express high 
levels of p-AKT Ser473 and Thr308 in the presence of PTEN(35). PTEN is also reported to 
play a broader AKT-independent tumor suppressive role via protein- and lipid-phosphatase 
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activities to mediate p53, cell cycle arrest and integrin, insulin and focal adhesion kinase 
signaling, reviewed in(40). Thus, developing our combined understanding of AKT regulation, 
p110 PI3K isoform signaling, and PTEN mode of action during prostate cancer is vital to 
determine optimal therapeutic approaches that inhibit the PI3K signaling network and 
subsequently prostate cancer growth and progression.  
 
Although p110 and p110β isoforms have been shown to form mutually exclusive signaling 
complexes with RAS and RHO family (RAC1/CDC42) small GTPase protein superfamily 
members respectively(22), the molecular mechanisms underpinning their different modes of 
action are poorly understood. This study provides additional data that underlines a distinct 
role for the RAC1-p110 signaling axis in Pten-deleted prostate cancer, and raises the 
possibility that RAC inhibition may show therapeutic efficacy against PTEN-deleted prostate 
cancer in the clinic, as recently demonstrated for a Pten-null, p110-dependent mouse model 
of myeloid neoplasia(41). By taking this approach, PI3K-independent functions of PTEN and 
AKT may be advantageously co-targeted, as RAC1 activation is mediated by PI3K-
dependent (e.g. PREX-1/TIAM/mTORC2) and PI3K-independent (e.g. SRC/p130CAS) 
signaling(25,42).   
 
We have generated a new clinically relevant transgenic mouse model of advanced prostate 
cancer driven by concomitant Pik3ca heterozygous oncogenic mutation and Pten 
homozygous deletion. We show that these two oncogenic drivers cooperate to promote rapid 
progression to invasive prostate cancer, characterised by the synergistic elevation of 
mTORC1/2 signaling, AKT super-activation and increased Pik3ca/b mRNA transcript 
expression. These data provide direct evidence that Pik3ca mutation and Pten deletion 
coordinate independent oncogenic signaling events during prostate cancer, in corroboration 
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with the distinct RPPA profiles observed. Furthermore, our findings emphasize that the co-
existence of mutated PIK3CA and PTEN loss may prove to be an important prognostic 
indicator for rapid prostate cancer progression and de novo resistance to androgen deprivation 
therapy in the clinic.  
 
Currently, the cause and consequence of upregulated Pik3ca/b transcription is poorly 
understood. Theoretically, increased Pik3ca/b gene expression could promote prostate cancer 
progression in Pik3ca
+/HR
;Pten
fl/fl
  mice by increasing p110 protein levels, and thus total 
PI3K activity, as PIK3CA amplification is thought to do in ovarian cancer cells (43). 
FOXO3A, NF-kB, YB1 and p53 have been shown to promote PIK3CA transcription 
(reviewed in(44)), however PIK3CB transcriptional regulators remain to be identified. 
Further investigation is needed to determine the underlying mechanism by which increased 
p110 catalytic activity and loss of Pten phosphatase activity cooperate to upregulate Pik3ca 
and Pik3cb transcription, and to establish the functional significance of this observation.  
 
Despite numerous phenotypic differences, we report that both Pten-null and Pik3ca
+/HR
-
driven prostate cancers are partially sensitive to androgen withdrawal and acquire CRPC in 
association with augmented PI3K signaling. These data signify that both p110 and p110 
PI3K catalytic isoforms can induce PI3K signaling in response to androgen deprivation, 
supporting previous in vitro work in the PTEN-deficient human prostate cancer LNCaP cell 
line that showed PI3K signaling induced by an AR-inhibitor is diminished by p110 or 
p110 inhibition(26). Since, AKT-hyperactivation and augmented mTORC1/2 are consistent 
features of intact Pik3ca
+/HR
;Pten
fl/fl
 prostate tumors, it is tempting to speculate that AKT-
hyperactivation may be a pre-requisite for de novo CRPC in this setting. In addition, innate 
CRPC in Pik3ca
+/HR
;Pten
fl/fl
 compound mutants was associated with increased 
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phosphorylation of the mTORC2-SGK substrate NDRG1 at Thr346, suggesting that NDRG1 
inactivation may facilitate de novo CRPC. Significantly, NDRG1 has been shown to function 
as a metastasis suppressor in mouse xenograft models of prostate cancer by reducing 
Activating Transcription Factor 3 (ATF3) transcription, and NDRG1 mRNA down-regulation 
correlates with Gleason score and worse prostate cancer survival(45). Stein and colleagues 
have also reported that NDRG1 is a p53 transcriptional target that is required for p53-
mediated apoptosis(46). Given that Pik3ca
+/HR
;Pten
fl/fl
 prostate tumors evade castration-
induced apoptosis and proliferation arrest, it will be important for future studies to determine 
if NDRG1 inactivation contributes to CRPC transition. However, since oncogenic PI3K/AKT 
signaling has been linked to increased genomic instability(47), we do not exclude the 
possibility that Pik3ca
+/HR
;Pten
fl/fl
 prostate tumors create an environment capable of inducing 
additional oncogenic mutations that promote CRPC formation.  
 
It is becoming clear that approaches inhibiting multiple targets within the PI3K network, 
either simultaneously or sequentially, are necessary to enhance therapeutic efficacy. Thus, 
further characterization of p110-mediated signaling, PI3K-independent PTEN tumor 
suppressive functions, AKT-independent signaling and AKT regulation is required to 
improve our understanding of how to target the PI3K network and identify mechanisms of 
therapeutic resistance to improve our management of prostate cancer in the clinic. Future 
work addressing how to personalise treatment for tumors driven by diverse PI3K genetic 
drivers is paramount, and is likely to entail the co-inhibition of PI3K-dependent and 
PI3K/AKT-independent signaling pathways.   
 
Materials and Methods 
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Experimental animals: PBiCre transgenic mice that express Cre recombinase under the 
control of the Probasin promoter and Pten
fl/fl
 mice have been described previously(21,48). 
Pik3ca
H1047R
 mutant mice were generated in-house(11). All mice were maintained on a pure 
FVB/NJ background. Mice were genotyped from DNA isolated from toe biopsies, as 
described previously(11,49). Age-matched males were randomly assigned to 
uncastrated/castrated cohorts. Castration experiments involved the surgical removal of the 
testis and epididymis. Animal experiments followed the National Health and Medical 
Research Council (NHMRC) Australian Code of Practice for the Care and Use of Animals 
for Scientific Purposes and were approved by the Animal Experimentation Ethics Committee 
at Peter MacCallum Cancer Centre.  
 
Tissue isolation and histology: Tissue was harvested and fixed for 16-24 h in 10% neutral-
buffered formaldehyde at 4C before being paraffin embedded and sectioned at 4 m. 
Sections were stained with haematoxylin/eosin for histological analysis by a certified 
pathologist (P.W.) blinded to genotype/treatment. Defining characteristics for prostate disease 
were based upon the pathological classification of mouse prostate disease outlined in (50). 
 
Immunohistochemistry: Staining was carried out as described previously(49) on formalin-
fixed, paraffin-embedded (FFPE) sections. Primary antibodies: Active RAC1-GTP 1:800 
(#26903, NewEast Biosciences), AR 1:300 (#sc-816, Santa Cruz), PCNA 1:400 (#610665, 
BD Biosciences Pharmingen), and Cell Signalling Technology antibodies: Cleaved Caspase-3 
1:300 (#9664), p-AKT (Ser473) 1:400 (#4060), p-AKT (Thr308) 1:400 (#13038), p-ERK 
(Thr202/Tyr204) 1:200 (#4376), PTEN 1:300 (#9559), p-RPS6 (Ser235/236) 1:400 (#2211), 
p-NDRG1 (Thr346) 1:800 (#5482) and p-4E-BP1 (Thr37/46) 1:200 (#2855). IHC scoring 
represents the mean percentage of positive cells counted from 8-10 images/mouse (200x 
magnification, BX-51 Olympus microscope, n=3/genotype).  
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PI3K inhibitor administration: Cohorts of male Pik3ca
+/HR
 or Pten
fl/fl
 mice were treated at 
400 and 200 d old respectively: A66 (p110-specific inhibitor, 100 mg/kg, daily p.o.), TGX-
221 (p110-specific inhibitor, 30 mg/kg, daily p.o.) and BKM120 (pan-PI3K inhibitor, 40 
mg/kg, daily p.o.). Inhibitors were dissolved in filter-sterilised 20% hydroxyproyl-beta-
cyclodextrin (Sigma), sonicated for 10 minutes and dosed immediately (4 weeks; 5 d on, 2 d 
off). No appreciable toxicity was observed (i.e. >20% weight loss). A66 and TGX-221 were 
generated in house by P.R.S. (University of Auckland, New Zealand) and BKM120 was 
obtained from SYNkinase (Australia).  
 
RNA isolation and QRT-PCR analysis: Total RNA extraction from mouse prostate tissue and 
QRT-PCR were performed according to standard methods described in supplementary 
methods.  
 
RNA in situ hybridisation: FFPE mouse prostate tissue sections were probed using the 
RNAscope® 2.5 high-definition red detection kit (#322350, Advanced Cell Diagnostics). 
Slides were counterstained with hematoxylin. Scoring represents the average number of RNA 
molecules per 50 cells/mouse (400x magnification, BX-43 Olympus microscope, 
n=3/genotype). 
 
RPPA: Protein lysates were prepared from snap frozen tissue homogenized in CLB1 buffer 
(Zeptosens, Bayer), and quantified using a Pierce™ Coomassie Plus (Bradford) Protein 
Assay Kit (n=3/cohort). Using a Sciclone/Caliper ALH3000 liquid handling robot (Perkin 
Elmer), samples were serially diluted in 10% CLB1:90% CSBL1 buffer (Zeptosens, Bayer) 
and spotted onto ZeptoChips (Zeptosens) in duplicate using a Nano-plotter-NP2.1 non-
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contact microarray system (GeSim). Chips were blocked under non-contact conditions for 1 
hour with BB1 buffer (Zeptosens), incubated with pre-validated primary antibodies (1:500, 
20 hours), and Alexa Fluor® 647 anti-rabbit secondary antibody (1:1000, 4 hours) (#Z-
25308, Thermo Fisher Scientific). Chips were read on a Zeptosens instrument and software 
version 3.1 used to calculate the relative fluorescence intensity. All samples were normalised to 
the background values reported in the secondary antibody-only negative control. Pearson’s 
correlation was calculated to confirm replicate pairs were adequately correlated (correlation 
coefficient >0.9). Data were Log2-normalised, median centered and re-scaled between 0-1 
using the formula; 
𝑎𝑏−min(𝑎𝑏)
max(𝑎𝑏)−min⁡(𝑎𝑏)
. 𝑎𝑏 represents a vector of antibody responses for a given 
sample. The RPPA heatmap was generated in R using pheatmap.  For details on Western 
blotting validation see supplementary methods.  
Analysis of genomic datasets: Analysis of PIK3CA gene mutation/amplification was 
performed on prostate cancer patient datasets with sequencing and copy number alteration 
(CNA) data using the cBioPortal platform(14). The TCGA provisional dataset was 
downloaded from the TCGA data portal (https://tcga-data.nci.nih.gov/); PIK3CA segment 
mean Log R-Ratio ≥0.135. To minimise CNA noise, probe number was filtered to ≤10. Silent 
mutations were excluded. 
 
Statistical analysis: Prostate weight and IHC scoring were analysed using a one-way 
ANOVA with Tukey’s correction or an unpaired t-test (95% confidence interval) as indicated 
using GraphPad Prism_7.03 software. Kaplan-Meier plots were generated, and age-adjusted 
COX proportional hazard regression ratio calculated using R software. For RPPA, an 
unpaired two-tailed t-test with Welch’s correction was calculated using R software. P<0.05 
was considered statistically significant.   
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Figure legends 
 
Figure 1. PIK3CA somatic mutation and amplification frequency in prostate cancer. (A) 
Histogram displaying PIK3CA mutation and copy number amplification/gain frequency 
across 9 prostate cancer genomic datasets. Pie charts show the distribution of primary and 
metastatic samples for each genomic dataset. (B) Schematic diagram of p110 illustrating 
mutation frequency across the 9 prostate cancer datasets analysed in relation to the core 
functional domains. Codons with frequent missense mutations at common hotspots are 
labelled magenta. To our knowledge, the 4 genetic alterations in light grey text have not been 
previously reported in other human malignancies, and their impact on p110 function is 
unknown. p85 = PI3K p85 regulatory subunit binding domain; RBD = RAS binding domain; 
C2 = calcium-dependent phospholipid-binding domain; Helical = PI3K helical domain; 
Kinase = PI3/4-kinase domain; aa = amino acid. (C) Kaplan-Meier plot comparing the 
survival probability of PIK3CA mutation and/or amplification/gain carriers with PIK3CA 
unaltered patients within the TCGA provisional prostate cancer patient dataset. PIK3CA age-
adjusted COXPH HR: 0.55, *P=0.023*. 
 
Figure 2. Heterozygous Pik3ca
H1047R
 oncogenic mutation causes invasive prostate cancer 
in mice that does not phenocopy Pten-deletion. (A) Representative H&E images of Wt, 
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Pik3ca
+/HR
 and Pten
fl/fl 
dorsolateral prostate epithelium (scale bar: 100 m). (B) Histogram 
displaying phenotype incidence in Wt, Pik3ca
+/HR
 and Pten
fl/fl 
dorsolateral prostate. DLP = 
dorsolateral prostate, PIN = prostate intraepithelial neoplasia. (C) Bar chart displaying total 
prostate weight normalised to body weight for Wt, Pik3ca
+/HR
 and Pten
fl/fl
 mice. n = as 
indicated (N). Error bars: SEM, *P<0.05 compared to Wt, one-way ANOVA with Tukey’s 
multiple comparison test.    
 
Figure 3. Pten
 
deletion triggers mTORC2 signaling to facilitate rapid prostate cancer 
progression relative to Pik3ca
H1047R
 mutation. (A) IHC to detect the proliferation marker 
PCNA in Wt, Pik3ca
+/HR
 and Pten
fl/fl 
prostate carcinoma at 400 d of age (scale bar: 50 m). 
(B) Quantitation of PCNA-positive nuclei in Wt, Pik3ca
+/HR
 and Pten
fl/fl
 prostate epithelium 
(n=3, *P<0.05 compared to Wt, or as indicated, one-way ANOVA with Tukey’s multiple 
comparison test. Error bars: SEM). (C) Representative IHC images to detect PTEN, 
mTORC1 signaling components (p-AKT Thr308, p-RPS6 Ser235/236 and p-4E-BP1 
Thr37/46) and mTORC2 substrates (p-AKT Ser473 and p-NDRG1 Thr346) in Wt 
dorsolateral prostate and Pik3ca
+/HR
 and Pten
fl/fl
 prostate carcinoma at 400 d of age (n=3, 
scale bar: 50 m, insert scale bar: 10 m). IHC quantitation for (D) p-AKT Thr308, (E) p-
RPS6 Ser235/236, (F) p-4E-BP1 Thr37/46, (G) p-AKT Ser473 and (H) p-NDRG1 Thr346 in 
Wt dorsolateral prostate and Pik3ca
+/HR
 and Pten
fl/fl
 prostate carcinoma at 400 d of age (n=3, 
Error bars: SEM, *P< 0.05 compared to Wt, or as indicated, one-way ANOVA with Tukey’s 
multiple comparison correction). 
 
Figure 4. Pik3ca
+/HR
 prostate cancer is p110-dependent, whereas Ptenfl/fl prostate 
cancer is p110 and p110 co-dependent. Representative IHC images to detect (A) p-ERK 
Thr202/Tyr204 and (B) Active RAC1-GTP in Wt dorsolateral prostate and Pik3ca
+/HR
 and 
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Pten
fl/fl
 prostate carcinoma at 400 d of age (n=3, Low magnification scale bar: 100 m, high 
magnification scale bar: 10 m). Bar chart indicating total prostate weight normalised to 
body weight for Pik3ca
+/HR
 mice (C) and Pten
fl/fl
 mice (D) with prostate carcinoma 
administered with either vehicle, p110-specific inhibitor (A66), p110-specific inhibitor 
(TGX-221), pan-PI3K inhibitor (BKM120) or A66 + TGX-221 for 4 weeks compared to age-
matched Wt controls. n = as indicated (N). Error bars: SEM, *P<0.05 compared to vehicle, 
one-way ANOVA with Tukey’s multiple comparison correction, ns = not significant. (E) 
Histogram displaying phenotype incidence for dorsolateral prostate from Pik3ca
+/HR
 and 
Pten
fl/fl
 mice treated with either vehicle, p110-specific inhibitor (A66), p110-specific 
inhibitor (TGX-221), pan-PI3K inhibitor (BKM120) or A66 + TGX-221 for 4 weeks. 
 
Figure 5. Pik3ca mutation and Pten
 
loss cooperate to accelerate prostate cancer 
progression in mice by upregulating proliferation and mTORC1/2 signaling. (A) 
Representative IHC images of Pik3ca
+/HR
;Pten
fl/fl
 prostate carcinoma at 56 and 100 d of age 
(scale bar: 100 m). (B) Phenotype incidence histogram for Wt, Pik3ca+/HR, Ptenfl/fl and 
Pik3ca
+/HR
;Pten
fl/fl
 dorsolateral prostate at 56 and 100 d of age. (C) IHC to detect PCNA in 
Pik3ca
+/HR
, Pten
fl/fl 
and
 
Pik3ca
+/HR
;Pten
fl/fl
 stage-matched prostate carcinomas (scale bar: 50 
m). IHC quantitation for (D) PCNA, (E) p-AKT Thr308, (F) p-RPS6 Ser235/236, (G) p-4E-
BP1 Thr37/46, (H) p-AKT Ser473 and (I) p-NDRG1 Thr346 in Pik3ca
+/HR
, Pten
fl/fl 
and
 
Pik3ca
+/HR
;Pten
fl/fl
 stage-matched prostate carcinomas (n=3, *P<0.05 compared to Pik3ca
+/HR
 
or as indicated, one-way ANOVA with Tukey’s correction. Error bars: SEM). (J) RNA in situ 
hybridisation analysis of Pik3ca and Pik3cb transcripts in Pik3ca
+/HR
, Pten
fl/fl 
and
 
Pik3ca
+/HR
;Pten
fl/fl
 stage-matched prostate carcinomas (n=3, scale bar: 50 m, insert scale 
bar: 5 m). Quantitation of (K) Pik3ca and (L) Pik3cb mRNA molecules detected by in situ 
hybridisation in Pik3ca
+/HR
, Pten
fl/fl 
and
 
Pik3ca
+/HR
;Pten
fl/fl
 stage-matched prostate carcinomas 
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(n=3, *P<0.05 compared to Wt, one-way ANOVA with Tukey’s correction. Error bars: 
SEM). 
 
Figure 6. Pik3ca
+/HR
 and Pten
fl/fl 
prostate cancers acquire CRPC, while 
Pik3ca
+/HR
;Pten
fl/fl
 compound mutants display innate resistance to castration. (A) Bar 
chart displaying total prostate weight normalised to body weight for Pik3ca
+/HR
 and Pten
fl/fl
 
mice 2 and 10 weeks post-castration relative to age-matched/uncastrated controls. n = as 
indicated (N). Error bars: SEM, *P<0.05, one-way ANOVA with Tukey’s correction. (B) 
Representative H&E images of Pik3ca
+/HR
 and Pten
fl/fl
 uncastrated dorsolateral prostate, and 2 
and 10 weeks post-castration (scale bar: 100 m). (C) Representative H&E images of 
Pik3ca
+/HR
;Pten
fl/fl
 uncastrated dorsolateral prostate and 2 weeks post-castration (scale bar: 
100 m, n = 5). (D) Bar chart displaying total prostate weight normalised to body weight for 
Pik3ca
+/HR
:Pten
fl/fl
 mice 2 weeks post-castration relative to age-matched/uncastrated controls 
(Error bars: SEM, P=0.3394, unpaired, two-tailed t-test, n = 5). IHC quantitation for (E) 
PCNA and (F) Cleaved-Caspase 3 (CC3) in Pik3ca
+/HR
, Pten
fl/fl
 and Pik3ca
+/HR
;Pten
fl/fl
 
dorsolateral prostate 2 weeks post-castration compared to uncastrated/age-matched controls. 
Error bars: SEM, *P<0.05, one-way ANOVA with Tukey’s correction, n = 3. Mice were 
castrated when prostate carcinoma was prevalent; Pik3ca
+/HR
 = 400 d old, Pten
fl/fl
 = 200 d old 
and Pik3ca
+/HR
;Pten
fl/fl
 =100 d old. 
  
Figure 7. De novo CRPC in Pik3ca
+/HR
;Pten
fl/fl
 double transgenic animals correlates with 
NDRG1 inactivation. Quantitation of IHC to detect mTORC1 signaling components (A) p-
AKT Thr308, (B) p-RPS6 Ser235/236, (C) p-4E-BP1 Thr37/46, (D) p-AKT Ser473 and (E) 
p-NDRG1 Thr346 in Pik3ca
+/HR
, Pten
fl/fl
 and Pik3ca
+/HR
;Pten
fl/fl
 prostate tissue 2 weeks post-
castration compared to uncastrated, age-matched controls (n = 3, Error bars: SEM, *P<0.05, 
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one-way ANOVA with Tukey’s multiple comparison correction). (F) Representative IHC 
images of p-NDRG1 Thr346 in Pik3ca
+/HR
, Pten
fl/fl
 and Pik3ca
+/HR
;Pten
fl/fl
 prostate tissue 2 
weeks post-castration compared to uncastrated, age-matched controls (scale bar: 50 m, n = 
3). (G) RPPA analysis was performed on lysates from Pik3ca
+/HR
, Pten
fl/fl
 and 
Pik3ca
+/HR
;Pten
fl/fl
 prostate tissue 2 weeks post-castration, and compared to uncastrated, age-
matched controls. Heatmap represents Log2 normalised and median centred data (means of 
duplicates, n = 3 per cohort). Mice were castrated when prostate carcinoma was prevalent; 
Pik3ca
+/HR
 = 400 d old, Pten
fl/fl
 = 200 d old and Pik3ca
+/HR
;Pten
fl/fl
 =100 d old. 
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